LatchBio raises $28M Series A to deliver modern data analytics stack to biologists

SAN FRANCISCO–(BUSINESS WIRE)–LatchBio, a company that accelerates the pace of scientific progress by enabling researchers to store and analyze data without touching code or cloud infrastructure, today announced a Series A funding round of $28 million co-led by Coatue and existing investor Lux Capital. Hummingbird Ventures, Caffeinated Capital and existing investors Haystack and Fifty Years also participated.

The LatchBio platform is a streamlined web-based solution designed to overcome bottlenecks in biotechnology research caused by the massive datasets generated by modern experiments. Using any browser, researchers can quickly import files from existing data stacks and access dozens of popular bioinformatics pipelines and data visualization tools, including RNA-Seq, CRISPResso2, and AlphaFold. As bioinformaticians download workflows through the LatchBio SDK, no-code interfaces are automatically created for biologists who are now empowered to integrate, process and visualize data in one place. Experience data can be stored and processed at any scale using a serverless data infrastructure, dramatically reducing the time and resources needed to move from experience to insight.

Scientists from leading industry organizations, including the Innovative Genomics Institute (IGI), BitBio, and Eligo Bioscience, leverage the power of the LatchBio platform to advance their work.

“The datasets generated by today’s scientific experiments are growing at an exponential rate, but many biologists lack the computational tools they need to quickly analyze and iterate using the results of their experiments,” said David. Cahn, General Partner of Coatue. “Coatue is excited to support LatchBio’s ambition to create the infrastructure needed to accelerate the pace of discovery and translational research – and most importantly, to help bring more lifesaving therapies into the clinic.”

“Since leading the seed cycle of LatchBio, we have been impressed with the dedication, focus and speed with which the team is building solutions that will have a significant impact on the way science is conducted in the lab. on a daily basis,” said Brandon Reeves, partner at Lux Capital. . “We are thrilled to once again support this founding team and their vision to address some of the computing and logistical challenges faced by those working at the cutting edge of science.”

“The Latch team is extremely proud to be backed by experienced investors who believe in our mission to build tools that accelerate humanity’s ability to engineer biology,” said Alfredo Andere, co-founder and CEO. by LatchBio. “We remain obsessively focused on building a platform that hosts the best bioinformatics workflows and other tools that scientists love to use and enable them to accelerate scientific progress.”

About LatchBio

LatchBio is a San Francisco-based company whose mission is to build and deliver the data infrastructure for the bioinformatics revolution. The company’s cloud-based platform offers no-code bioinformatics for scientists looking to store, transform and visualize their data. Using any web browser, the global scientific community can quickly access popular bioinformatics pipelines and data visualization tools. For company updates, visit latch.bio.

Comments are closed.